Skip to Content

Press Releases

Blumenthal, Beyer Lead Bicameral Push For Boost Of Health Care System Research Funding In Next Congressional COVID-19 Relief Package

“The results of these investments will guide health care policy making and delivery system operations, helping the nation learn from its experiences meeting the COVID-19 challenge and better preparing us to meet a future crisis.”

U.S. Senator Richard Blumenthal (D-CT) and U.S. Representative Don Beyer (D-VA) led a group of 32 Members of Congress in urging Congressional leadership to include $71 million in funding for the Agency for Healthcare Research and Quality (AHRQ) in the next COVID-19 relief package. This funding would give AHRQ the capacity to evaluate the U.S. health care system’s response to the pandemic, pinpoint shortcomings, and improve national preparedness for future crises. AHRQ is the country’s sole federal agency focused on generating research to advance health care delivery system efficiency.

“AHRQ-funded research and databases allow us to understand where waste, inefficiencies, and gaps exist within the health care system, and allows patients, payers, providers, and others to harness American innovation and make the health care system safer, more efficient, and more effective,” the Senators wrote in a letter to Senate Majority Leader Mitch McConnell (R-KY), Minority Leader Chuck Schumer (D-NY), and Senate Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies Chairman Roy Blunt (R-MS) and Ranking Member Patty Murray (D-WA). A similar letter was sent to House leadership. “This research and focus makes AHRQ indispensable in our efforts to respond to, understand, and mitigate the effects of COVID-19 in our healthcare system. No other HHS agency is currently engaged in evaluating the health care sector’s response to this pandemic.”

Among other priorities, the Members of Congress emphasized the need to have AHRQ evaluate telehealth obstacles for vulnerable populations, as well as telehealth privacy concerns, deficiencies in the supply chain resulting in ventilator and personal protective equipment shortages, and care delivery, planning, and capacity shortfalls.

The Senate letter was also signed by U.S. Senators Chris Van Hollen (D-MD), Dianne Feinstein (D-CA), Elizabeth Warren (D-MA), and Michael Bennet (D-CO). The House of Representatives letter was also signed by U.S. Representatives Betty McCollum (D-MN), Bennie G. Thompson (D-MS), David Trone (D-MD), Lucille Roybal-Allard (D-CA), Stephen F. Lynch (D-MA), Val Demings (D-FL), Jamie Raskin (D-MD), Vicente Gonzalez (D-TX), Bill Foster (D-IL), Alan Lowenthal (D-CA), Terri A. Sewell (D-AL), Katie Porter (D-CA), Steve Cohen (D-TN), Jahana Hayes (D-CT), Debbie Dingell (D-MI), Bill Pascrell, Jr. (D-NJ), Gerry Connolly (D-VA), Adam Smith (D-WA), Suzanne Bonamici (D-OR), Abigail Spanberger (D-VA), Jason Crow (D-CO), Danny Davis (D-IL), Lucy McBath (D-GA), Lisa Blunt Rochester (D-DE), and John Yarmuth (D-KY).

The full text of the letter to Senate leadership is available here and below. The full text of the letter to House leadership is available here.

 

May 7, 2020

 

The Honorable Mitch McConnell                              The Honorable Chuck Schumer

Majority Leader                                                          Minority Leader

United States Senate                                                   United States Senate

The Capitol, S-230                                                      The Capitol, S-221

Washington, DC 20510                                              Washington, DC 20510

 

The Honorable Roy Blunt                                          The Honorable Patty Murray

Chair                                                                           Ranking Member

Senate Appropriations Subcommittee                        Senate Appropriations Subcommittee

on Labor, Health and Human Services,                      on Labor, Health and Human Services,

Education and Related Agencies                                Education and Related Agencies

136 Dirksen Senate Building                                      160 Dirksen Senate Building

Washington, DC 20510                                              Washington, DC 20510

 

 

Dear Majority Leader Mitch McConnell, Minority Leader Chuck Schumer, Chairman Blunt, and Ranking Member Murray:

We are writing to respectfully request that you include $71 million for the Agency for Healthcare Research and Quality (AHRQ) in the next FY20 emergency supplemental appropriations bill. This funding will support evaluations and research related to the health care system’s response to the COVID-19 virus.

COVID-19 is a watershed moment for our country. The United States health care system must quickly learn from and adjust to what’s happening now so that we can respond better and more quickly in the event of a recurrence or in response to the next pandemic.  In particular, we must quickly and carefully conduct assessments of the health care system’s response to COVID-19 with a particular focus on identifying successful and scalable measures taken to address this crisis.

AHRQ is the only federal agency whose sole focus is to generate reliable research on how to deliver the highest quality care, at the greatest value, with the best outcomes to all patients. It is the only agency that funds research on the “real-world” patient—the one who doesn’t have diabetes alone, for example, but also has cardiovascular disease and renal disease; or the patient who has cancer, as well as heart disease. AHRQ-funded research and databases allow us to understand where waste, inefficiencies, and gaps exist within the health care system, and allows patients, payers, providers, and others to harness American innovation and make the health care system safer, more efficient, and more effective. This research and focus makes AHRQ indispensable in our efforts to respond to, understand, and mitigate the effects of COVID-19 in our health care system. No other HHS agency is currently engaged in evaluating the health care sector’s response to this pandemic.

In particular, we believe the following issues require in-depth research and analysis:

•   the rapid expansion of telehealth in response to social distancing policies, including identifying obstacles to access for veterans, the elderly, and low income communities, and gaps in compliance with health care privacy and security rules;

•   the deficiencies in the health care system’s supply chain that have manifested in ventilator and personal protective equipment (PPE) shortages, and;

•   the shortfalls in health care delivery planning, coordination, and capacity.

AHRQ’s research will uniquely focus on how health care systems and professionals responded to this crisis, how they successfully reorganized care delivery and care across a variety of settings, and what unmet delivery needs must be addressed.  The results of these investments will guide health care policy making and delivery system operations, helping the nation learn from its experiences meeting the COVID-19 challenge and better preparing us to meet a future crisis.

AHRQ has the mandate and proven track record to deliver timely results that identify what works – and what doesn’t – in health care delivery. The Agency should have the funds to begin to assess the impact of the changes made to law, regulation and medical practice immediately. We urge you to include the $71 million in funding for AHRQ within the next COVID19 response package. Thank you for your time and attention to our request.

 

Sincerely,

-30-